Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Tokushukai Preparing Model Formulary for 72 Group Hospitals; PPIs, Flu Drugs Eyed
April 14, 2020
- Daiichi Sankyo, Nagoya Institute of Technology, Mitsubishi UFJ Capital Pair Up on Research for Vision Restoration Gene Therapy
April 14, 2020
- Daiichi Sankyo Staffer in Toyama Infected with Coronavirus
April 14, 2020
- Healios to Enroll COVID-19 Patients in PII Off-the-Shelf Cell Therapy Program for ARDS
April 14, 2020
- Shimadzu to Roll Out Coronavirus Detection Regent Kit on April 20
April 14, 2020
- After Valsartan, Towa Now Curbing Clindamycin Supplies as India Lockdown Continues
April 13, 2020
- Astellas’ AML Drug Xospata Accepted for Review in China
April 13, 2020
- Chugai Shifting Resources to Beef Up Drug Discovery Prowess: New Chief
April 13, 2020
- Manufacturer Restresses Caution against BCG Vaccine’s Off-Label Use for COVID-19
April 10, 2020
- Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- No Impact from Coronavirus Outbreak Seen with February Detailing Number: Intage
April 10, 2020
- Indian Export Restriction Lifted, but Japan Imports Still Stalled
April 10, 2020
- Astellas Boosts COVID-19 Measures after State of Emergency Declared; Daiichi Sankyo Partially Pausing Trials
April 10, 2020
- Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
- MSD Introduces AI Chatbot for Information Provisioning of Keytruda
April 9, 2020
- FunPep Joins AnGes, Osaka Univ. Partnership to Develop Novel Coronavirus Vaccine
April 9, 2020
- Chugai to Launch Actemra PIII Trial for Coronavirus
April 9, 2020
- Roche Diagnostics Launches Coronavirus Test in Japan
April 8, 2020
- Japan Ethical Drug Sales Up 0.1% in February: Crecon
April 8, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…